- Home
- IONS vs AES Comparison
IONS vs AES Comparison
Compare IONS & AES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- AES
- Stock Information
- Founded
- IONS 1989
- AES 1981
- Country
- IONS United States
- AES United States
- Employees
- IONS N/A
- AES N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- AES Electric Utilities: Central
- Sector
- IONS Health Care
- AES Utilities
- Exchange
- IONS Nasdaq
- AES Nasdaq
- Market Cap
- IONS 6.0B
- AES 7.1B
- IPO Year
- IONS 1991
- AES 1991
- Fundamental
- Price
- IONS $32.32
- AES $10.58
- Analyst Decision
- IONS Buy
- AES Buy
- Analyst Count
- IONS 19
- AES 11
- Target Price
- IONS $61.24
- AES $20.40
- AVG Volume (30 Days)
- IONS 1.7M
- AES 15.0M
- Earning Date
- IONS 02-19-2025
- AES 02-27-2025
- Dividend Yield
- IONS N/A
- AES 6.65%
- EPS Growth
- IONS N/A
- AES N/A
- EPS
- IONS N/A
- AES 1.44
- Revenue
- IONS $705,000,000.00
- AES $12,284,000,000.00
- Revenue This Year
- IONS N/A
- AES $0.37
- Revenue Next Year
- IONS $10.08
- AES $3.69
- P/E Ratio
- IONS N/A
- AES $7.37
- Revenue Growth
- IONS N/A
- AES N/A
- 52 Week Low
- IONS $30.23
- AES $9.88
- 52 Week High
- IONS $52.34
- AES $22.21
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- AES 42.84
- Support Level
- IONS $30.86
- AES $9.88
- Resistance Level
- IONS $34.74
- AES $10.91
- Average True Range (ATR)
- IONS 1.35
- AES 0.36
- MACD
- IONS 0.18
- AES 0.08
- Stochastic Oscillator
- IONS 46.34
- AES 66.13
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.